Ibspa10 mg

Ibspa (also known by the synonym dicyclomine) is a synthetic anticholinergic (antimuscarinic) antispasmodic agent used to relieve smooth-muscle spasm of the gastrointestinal tract.

Established / FDA-approved use

• Functional bowel syndrome / Irritable Bowel Syndrome (IBS): Ibspa is FDA-approved as adjunctive therapy for the symptomatic treatment of functional bowel/irritable bowel syndrome in adults, to help relieve abdominal cramping and spasm.

Guideline-supported / adjunct uses

• Generalized gastrointestinal (GI) spasm and colicky abdominal pain, including spasm associated with diverticulitis, as an adjunct to other measures (diet, fiber, stress management).

Off-label / regionally-labeled use (use with caution)

• In some markets, including Bangladesh, Ibspa is labeled for use in infantile colic in infants over 6 months of age and for urinary incontinence secondary to unstable detrusor (bladder) muscle. These uses are not FDA-approved indications, and Ibspa carries a well-documented contraindication in infants under 6 months (see Contraindications). Use in infants and young children should only be under direct physician supervision.

Ibspa is not a first-line or curative treatment for IBS; it manages symptoms and is typically used alongside dietary and lifestyle measures.

Each tablet/capsule of Dicycloverine Hydrochloride generally contains Dicycloverine Hydrochloride 10 mg or 20 mg as the active ingredient. An oral syrup formulation (approximately 10 mg/5 mL) and an injectable formulation (10 mg/mL, for intramuscular use only) are also available in some markets. Exact strengths, inactive ingredients, and available dosage forms vary by manufacturer and country — check the product label of the specific brand dispensed.

Ibspa is a synthetic tertiary amine antispasmodic and anticholinergic (antimuscarinic) agent chemically related to atropine, but with a different balance of anticholinergic and direct smooth-muscle relaxant (musculotropic) activity. It is a fine, white, crystalline, odorless powder that is freely soluble in water and alcohol.

Ibspa is used clinically to reduce excessive contraction and spasm of gastrointestinal smooth muscle, providing symptomatic relief of cramping and colicky abdominal pain, most notably in irritable bowel syndrome.

Ibspa belongs to the antispasmodic / anticholinergic (antimuscarinic) agents therapeutic class, specifically the gastrointestinal antispasmodic subgroup.

Mechanism of action

Dicycloverine Hydrochloride relieves smooth-muscle spasm through a dual mechanism:

• Anticholinergic (antimuscarinic) action: it competitively blocks acetylcholine at postganglionic muscarinic receptors on gastrointestinal smooth muscle, reducing spasm and motility (approximately one-eighth the potency of atropine on this receptor in vitro).
• Direct musculotropic (spasmolytic) action: it exerts a direct, non-anticholinergic relaxant effect on GI smooth muscle, including against bradykinin- and histamine-induced spasm.

Pharmacokinetics

• Absorption: Rapidly absorbed after oral administration; peak plasma concentration is reached within about 60–90 minutes.
• Distribution: Widely distributed into body tissues (large apparent volume of distribution).
• Metabolism: Metabolic pathways have not been fully characterized.
• Elimination: Predominantly renal, with a smaller fecal component; the terminal elimination half-life is longer than the initial distribution half-life, so effects can persist after plasma levels appear to fall.

• Ibspa tablets/capsules may be taken with or without food; taking with food may reduce nausea in some patients.
• Swallow tablets/capsules whole; do not crush or chew unless the specific product labeling allows it.
• The syrup formulation should be measured with an accurate oral dosing device, not a household spoon.
• The injectable form is for intramuscular use only and must be administered by a healthcare professional; it must never be given intravenously.
• Take Ibspa at evenly spaced intervals as directed by the prescriber.

Ibspa has well-documented interactions with the following agents:

• Other anticholinergic/antimuscarinic drugs (e.g., antihistamines, tricyclic antidepressants, phenothiazines/antipsychotics, other antiparkinsonian and antispasmodic agents, disopyramide, MAO inhibitors): additive anticholinergic effects (dry mouth, blurred vision, constipation, urinary retention, confusion) may occur; combination should be used cautiously.
• Antacids: may reduce absorption of Ibspa if taken at the same time; separate dosing by at least 1–2 hours.
• Digoxin: anticholinergic-induced slowing of GI motility can increase digoxin absorption and serum concentration; monitor for digoxin toxicity.
• Metoclopramide and other prokinetic agents: the GI motility-stimulating effect may be antagonized by Ibspa's antimuscarinic action.
• Opioid analgesics: additive risk of constipation and urinary retention.
• Amantadine and other drugs used for glaucoma: concurrent use may worsen anticholinergic effects or antagonize glaucoma therapy, potentially raising intraocular pressure — avoid in narrow/angle-closure glaucoma (see Contraindications).

This is not an exhaustive list; inform the prescriber of all other medicines being taken before starting Ibspa.

Side effects of Ibspa are mainly anticholinergic in nature and are dose-related.

Common (may affect more than 1 in 20 people)

• Dry mouth
• Dizziness and drowsiness
• Blurred vision
• Nausea
• Weakness (asthenia) and nervousness

Less common

• Constipation, bloating
• Urinary hesitancy or retention
• Palpitations, fast heart rate (tachycardia)
• Decreased sweating, insomnia
• Dilated pupils (mydriasis), increased eye pressure

Rare but serious

• Heat prostration (from decreased sweating in hot weather)
• Psychosis, delirium, or hallucinations (more common in elderly or sensitive individuals)
• Severe allergic/hypersensitivity reactions
• In infants (contraindicated use): serious breathing problems, seizures, and death — see Contraindications.

Report any severe or persistent side effect to a physician promptly.

Pregnancy

Adequate and well-controlled studies of Ibspa in pregnant women at recommended doses are lacking. Available epidemiologic data have not shown an increased risk of malformations with use during the first trimester, and animal reproduction studies at high multiples of the human dose have not shown fetal harm; however, this is not a guarantee of safety. Ibspa should be used during pregnancy only if clearly needed, after the potential benefit has been weighed against the potential risk to the fetus, and only under medical advice.

Lactation

Ibspa is contraindicated in nursing mothers. It is excreted into breast milk and has been associated with serious adverse reactions, including breathing difficulty, in breastfed infants. Breastfeeding mothers should not use Ibspa; a physician should be consulted about alternative therapy.

Use Ibspa with caution in the following situations, in addition to the absolute contraindications listed separately:

• Cardiovascular disease — tachyarrhythmia, thyrotoxicosis, congestive heart failure, coronary heart disease, or hypertension, as anticholinergic effects can increase heart rate.
• Hot weather / high ambient temperature — Ibspa decreases sweating and can predispose to heat prostration and hyperthermia; use caution during exercise or hot weather, especially in infants and the elderly.
• Autonomic neuropathy, hepatic or renal disease, prostatic hypertrophy — use cautiously; monitor for urinary retention or accumulation.
• Diarrhea — may be an early symptom of incomplete intestinal obstruction, especially in patients with an ileostomy or colostomy; do not treat diarrhea with Ibspa in this setting without medical evaluation.
• Elderly patients — increased sensitivity to anticholinergic effects (confusion, cognitive impairment, urinary retention, constipation); use the lowest effective dose and monitor closely.
• Ibspa may cause drowsiness, dizziness, or blurred vision — use caution when driving or operating machinery until the effect on the individual is known.

Overdose of Ibspa produces an anticholinergic toxicity picture, which may include headache, nausea and vomiting, blurred vision, dilated pupils, hot and dry flushed skin, dizziness, dry mouth, difficulty swallowing, central nervous system stimulation (restlessness, excitement) that can progress to CNS depression, convulsions, and neuromuscular blockade with respiratory paralysis in severe cases.

Suspected overdose is a medical emergency. Seek immediate medical attention or contact emergency services / a poison control center right away. Do not attempt to manage a suspected overdose at home. Hospital management may include supportive care, gastric decontamination, and, when indicated, treatment for anticholinergic toxicity under medical supervision.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use

Ibspa is contraindicated in infants under 6 months of age (see Contraindications). Safety and effectiveness in the general pediatric population have not been established by major regulatory authorities. In some countries, low-dose oral use is regionally labeled for infants over 6 months under direct physician supervision, but this should be approached cautiously and only when clearly needed.

Elderly (geriatric) use

Elderly patients are more susceptible to anticholinergic adverse effects, including confusion, urinary retention, and constipation. Use the lowest effective dose and monitor closely, particularly given the likelihood of reduced hepatic, renal, or cardiac function with age.

Renal impairment

Ibspa is substantially excreted by the kidney; use with caution in renal impairment, as toxic reactions may occur more readily.

Hepatic impairment

Use with caution, as the effect of hepatic impairment on Ibspa has not been formally studied.

Duration of Ibspa therapy should be individualized based on symptom response. A therapeutic trial of about 1–2 weeks is typical; if there is no adequate response, or if side effects require reducing the dose below 80 mg/day within 2 weeks, Ibspa should be discontinued and the diagnosis and treatment plan reassessed by a physician. Ibspa is not intended for indefinite, unsupervised long-term use without periodic medical review.

Anticholinergics; Antispasmodics; Gastrointestinal antispasmodic agents

Dicycloverine Hydrochloride acts through a dual mechanism on gastrointestinal smooth muscle: (1) an anticholinergic (antimuscarinic) effect that competitively blocks acetylcholine at muscarinic receptors, reducing spasm and motility, and (2) a direct musculotropic (spasmolytic) effect on smooth muscle that is independent of its anticholinergic activity. Together these actions relax GI smooth muscle and relieve cramping/spasm.

B

Ibspa is contraindicated in infants under 6 months of age due to a well-documented risk of serious respiratory symptoms (including apnea), seizures, and death in this age group. Safety and effectiveness in the broader pediatric population have not been established by the FDA. Where locally labeled for infantile colic in infants over 6 months, use should occur only under direct physician supervision, at the lowest effective dose, with close monitoring for anticholinergic effects. Parents/caregivers should never give Ibspa to an infant without a physician's explicit instruction.